| Literature DB >> 29094948 |
Estelle Juère1,2, Justyna Florek1, Meryem Bouchoucha2, Siddharth Jambhrunkar3,4, Kuan Yau Wong3,4, Amirali Popat3,4, Freddy Kleitz1,2.
Abstract
Sizing drugs down to the submicron and nanometer scale using nanoparticles has been extensively used in pharmaceutical industries to overcome the poor aqueous solubility of potential therapeutic agents. Here, we report the encapsulation and release of resveratrol, a promising anti-inflammatory and anticancer nutraceutical, from the mesopores of MCM-48-type silica nanospheres of various particle sizes, i.e., 90, 150, and 300 nm. Furthermore, the influence of the carrier pore size on drug solubility was also evaluated (3.5 vs 7 nm). From our results, it is observed that the saturated solubility could depend not only on the pore size but also on the particle size of the nanocarriers. Moreover, with our resveratrol-mesoporous silica nanoparticles formulation, we have observed that the permeability of resveratrol encapsulated in MCM-48 nanoparticles (90 nm) can be enhanced compared to a resveratrol suspension when tested through the human colon carcinoma cell monolayer (Caco-2). Using an in vitro NF-κB assay, we showed that resveratrol encapsulation did not alter its bioactivity and, at lower concentration, i.e., 5 μg mL-1, resveratrol encapsulation provided higher anti-inflammatory activity compared to both resveratrol suspension and solution. All combined, the reported results clearly highlight the potential of small size mesoporous silica nanoparticles as next generation nanocarriers for hydrophobic drugs and nutraceuticals.Entities:
Keywords: Caco-2 monolayer; anti-inflammatory; mesoporous silica nanoparticles; oral drug delivery; resveratrol; solubility
Mesh:
Substances:
Year: 2017 PMID: 29094948 DOI: 10.1021/acs.molpharmaceut.7b00529
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939